Melan-A/MART-1/AS02B/Montanide ISA vaccine (Ludwig/GlaxoSmithKline/Seppic)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMelan-A/MART-1/AS02B/Montanide ISA vaccine (Ludwig/GlaxoSmithKline/Seppic)
Drug Alias Namecancer vaccine (Ludwig/GlaxoSmithKline/Seppic)
ClassificationBiologics > Antigen > Tumor antigenVaccines > Application > Therapeutic vaccineBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSwedenSwitzerland +[4] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeppic SaLudwig Institute For Cancer ResearchGlaxosmithkline Biologicals SA
Active IndicationsN/A
Inactive IndicationsMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A